CJC-1295 + Tesamorelin Blend
GHRH analog (CJC-1295 no-DAC) + stabilized GHRH (Tesamorelin) blend
- Class
- Dual-GHRH blend (niche)
- Half-life
- Both ~30 min
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Weak / anecdotal
Overview
An uncommon blend. Both CJC-1295 (no-DAC) and Tesamorelin are GHRH analogs — they hit the SAME receptor (GHRH-R) with the SAME downstream effect (GH release from pituitary somatotrophs). Combining them is pharmacologically redundant in a way CJC+Ipamorelin or Tesa+Ipamorelin aren't (those add a second, distinct receptor mechanism via ghrelin / GHSR-1a).
The argument for this blend, from vendors and some users: tesamorelin's stabilising modifications (lipid tail + protected N-terminus) give it slightly different pharmacokinetics from CJC-1295 no-DAC; the combination might smooth the GHRH-receptor exposure curve. Editorial read: that's a thin theoretical benefit for double the GHRH cost. If you want a GH-secretagogue blend, CJC+Ipa or Tesa+Ipa is the better-evidenced choice.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved as a blend. Research-market product.
- Same safety profile as either single GHRH — no new mechanism means no new safety concerns specifically.
- Cost concern: this is the wrong product for almost everyone. Read the alternatives in 'How it works' before buying.
+ 2 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching CJC-1295 + Tesamorelin Blend.
- IGF-1 — should rise but no more than a single-GHRH at equivalent total dose
- Fasting glucose / HbA1c (GH antagonises insulin over months)
- Body composition over 12+ weeks
- Hand / foot tingling (IGF-1 overshoot)
- Cost vs alternatives — this blend is rarely worth the price premium
Frequently asked questions
What is CJC-1295 + Tesamorelin Blend?
GHRH analog (CJC-1295 no-DAC) + stabilized GHRH (Tesamorelin) blend. An uncommon blend. Both CJC-1295 (no-DAC) and Tesamorelin are GHRH analogs — they hit the SAME receptor (GHRH-R) with the SAME downstream effect (GH release from pituitary somatotrophs). Combining them is pharmacologically redundant in a way CJC+Ipamorelin or Tesa+Ipamorelin aren't (those add a second, distinct receptor mechanism via ghrelin / GHSR-1a).
How is CJC-1295 + Tesamorelin Blend administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of CJC-1295 + Tesamorelin Blend?
Both ~30 min — CJC-1295 (no-DAC) sc ~30 min · Tesamorelin sc ~26 min. Both clear fast..
Is CJC-1295 + Tesamorelin Blend approved for human use?
CJC-1295 + Tesamorelin Blend is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for CJC-1295 + Tesamorelin Blend?
Evidence tier: Weak / anecdotal. No human trial data exists for this specific blend. The components have their own data; the combination has zero.
What is commonly monitored when researching CJC-1295 + Tesamorelin Blend?
Commonly tracked markers + signals: IGF-1 — should rise but no more than a single-GHRH at equivalent total dose, Fasting glucose / HbA1c (GH antagonises insulin over months), Body composition over 12+ weeks, Hand / foot tingling (IGF-1 overshoot), Cost vs alternatives — this blend is rarely worth the price premium.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.